Use a Low-Molecular-Weight Heparin for Most Patients With Cancer-Associated VTE
September 2017
We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.
The role of DOACs (Eliquis, Xarelto, etc) is expanding. Chest guidelines now favor these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.
But don't recommend jumping to a DOAC first-line to treat or prevent recurrent VTE in patients with cancer. There's limited evidence about the efficacy and safety of DOACs in this case.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote